EPO and myocardial ischemia: Voors et al. (2010) found that GF for therapeutic angiogenesis represented by EPO was related to less major adverse cardiovascular events (MACE). Nevertheless, the study performed by Steppich et al. (2017) showed that GF for therapeutic angiogenesis did not promote target vessel revascularization in patients with IHD compared with placebo.